CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Home
/
update
/
details

Roche Announces Definitive Agreement to Acquire Poseida Therapeutics, Expanding Cell Therapy Portfolio and Platforms

NextEdge Admin

26 Nov 2024

2 min 23 sec

Poseida Therapeutics,cell therapy,autoimmune diseases

Roche has entered into a definitive agreement to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic CAR-T cell therapies. Based in San Diego, Poseida focuses on developing off-the-shelf CAR-T therapies for hematological malignancies, solid tumors, and autoimmune diseases. The acquisition builds on the 2022 partnership between the companies aimed at advancing CAR-T therapies for unmet medical needs.

Poseida’s leading programs include P-BCMA-ALLO1, an allogeneic CAR-T targeting BCMA, which has received FDA designations for relapsed/refractory multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR-T in Phase 1 trials for B-cell malignancies. This program is also being investigated for autoimmune diseases such as multiple sclerosis and lupus. Additional pipeline assets include P-MUC1C-ALLO1, a Phase 1 allogeneic CAR-T for solid tumors, and preclinical genomic medicine candidates.

The acquisition grants Roche access to Poseida’s GMP manufacturing facilities and expertise. Current Poseida employees will join Roche’s Pharmaceuticals Division, further strengthening Roche’s capabilities in cell therapy innovation.

“This acquisition accelerates our progress in allogeneic cell therapy and complements our ongoing partnership with Poseida,” said Levi Garraway, Roche’s Head of Product Development and Chief Medical Officer. “We are encouraged by the early clinical data and the potential for first-in-class therapies in oncology, immunology, and neurology.”

Aviv Regev, Head of Genentech Research & Early Development, added, “This collaboration combines cutting-edge science and expertise to harness the transformative potential of cell therapy.”

The acquisition underscores Roche’s commitment to pioneering medicines and expanding patient access to innovative therapies.